uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook
Historic Huntington’s Results: On September 24, 2025, uniQure revealed landmark Phase I/II trial results for its Huntington’s disease gene therapy AMT-130. In patients treated…

















